Unidade Local De Saude De Loures-Odivelas EPE — Clinical Trial Site

38 Registered trials

24 Currently recruiting

Organisation

Unidade Local De Saude De Loures-Odivelas EPE

Location

Loures, Portugal

Identifier

ORG-100041360

Address

Avenida Carlos Teixeira, 2674-514, Portugal

Departments

351004: Oncologia Medica
Centro de Investigação e Inovação
Department of Nephrology
Gastroenterology
Gastrology
Intensive Care Medicine
Medical Oncology
Nephrology
Neurology
Oncology
Oncology Departement
Oncology Department
Otorhinolaryngology Department
Pneumologia
Pneumology Department
Psychiatry
Pulmonology
Pulmonology Unit
Serviço de Gastrenterologia
Serviço de Nefrologia
Serviço de Oftalmologia, ULS-LOD
Serviço de Oncologia

Clinical trials at this site (38)

Search interface

A study to find an efficacious and safe dose of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis Pending

2024-514246-37-00 Idiopathic pulmonary fibrosis (IPF) 4
Study of Intravenous ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibros… Pending

2024-518013-25-00 Idiopathic Pulmonary Fibrosis 4
Clinical trial to assess the safety and tolerability of TP-122A for the treatment of ventilator-associated pneumonia. Pending

2025-521533-85-00 Ventilator-Associated Pneumonia 7
A Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis. Pending

2025-522373-10-00 Progressive pulmonary fibrosis and Idiopathic pulmonary 5
A study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with IV Bevacizumab Compared to Standard of Care IV Bevacizumab i… Recruiting

2025-521712-19-00 Colorectal Cancer 5 2026-07-06
A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting

2025-524498-17-00 Pretreated Unresectable Locally Advanced or Metastatic 10 2026-05-08
A study to find out if BI 764198 helps adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS) Recruiting

2025-522191-86-00 Focal segmental glomerulosclerosis 5 2026-04-02
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis Recruiting

2023-503699-25-00 Progressive Pulmonary Fibrosis 5 2024-07-15
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis Recruiting

2023-503697-21-01 Idiopathic pulmonary fibrosis 5 2024-06-24
Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting

2022-500273-14-00 Atherosclerotic cardiovascular disease in patients with 10 2023-07-17
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Ad… Recruiting

2025-521124-29-00 Non-Small Cell Lung Cancer 10 2026-02-13
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous… Recruiting

2025-520730-28-00 Common EGFR-Mutated Locally Advanced or Metastatic Non- 4 2025-12-08
A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting

2025-521382-27-00 Moderately to Severely Active Crohn's Disease 10 2025-12-04
Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting

2025-521381-10-00 Moderately to Severely Active Ulcerative Colitis 5 2025-12-03
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin i… Recruiting

2024-518365-10-00 Previously Untreated Advanced or Metastatic Non-Squamou 5 2025-10-28
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung… Recruiting

2024-517780-24-00 Lung Cancer 5 2025-09-18
A phase IV, multicentre, open-label, single-arm study to investigate the efficacy, safety and durability of faricimab (RO6867461) in caucasi… Recruiting

2024-515640-22-00 polypoidal choroidal vasculopathy 6 2025-08-06
Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION) Recruiting

2024-519521-37-01 Acute ischemic stroke 10 2025-07-30
A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE… Recruiting

2024-512360-55-00 Unresectable locally recurrent or metastatic hormone re 4 2025-06-30
A Study to Compare the Efficacy and Safety of Vedolizumab With and Without Upadacitinib in Adults With Moderately to Severely Active Crohn's… Recruiting

2023-509391-42-00 Chron's Disease 11 2025-06-02
A study to measure how well seltorexant works in adult depressed patients and how safe it is both for short- and long-term use when taken wi… Recruiting

2023-509070-36-00 Major Depressive Disorder with Insomnia Symptoms 5 2025-03-18